By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

This was the stock's second consecutive day of gains.

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we ...

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.